STADA Arzneimittel Stock Forecast for 2023 - 2025 - 2030
Updated on 04/25/2024
STADA Arzneimittel Stock Forecast and Price Target
STADA Arzneimittel's most recent price target of 0.00€ for 2024 was provided by renowned analysts over the past few months, with an average prediction of 0.00€. If this prediction is correct, STADA Arzneimittel's stock could rise by 100 percent from its current trading price. The potential increase for the stock is 0.00€ per share, with a possible range of 0.00€ to 0.00€. You may be interested in rivals even if you aren't interested in STADA Arzneimittel stock.
0.00% Upside
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$732.20 | Buy/Sell | $636.99 | 14.38% |
| PG Stock Forecast | Procter & Gamble | Outperform |
12
|
$162.60 | Buy/Sell | $166.80 | 6.05% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$148.53 | Buy/Sell | $174.55 | 14.45% |
| GSK Stock Forecast | GSK | Outperform |
12
|
£16.36 | Buy/Sell | £17.30 | 19.19% |
| RKT Stock Forecast | Reckitt Benckiser Group | Outperform |
12
|
£43.74 | Buy/Sell | £66.68 | 28.03% |
STADA Arzneimittel Revenue Forecast for 2023 - 2025 - 2030
In the last two years, STADA Arzneimittel's Revenue has grown by 26.14%, from 3.01€B to 3.80€B. In the following year, the 0 analysts surveyed believe that STADA Arzneimittel's Revenue will decrease by 12.07%, reaching 3.34€B. According to professionals, by 2030, STADA Arzneimittel's Revenue will have decreased by 11.32%, falling down to 3.37€B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAYN Stock Forecast | Bayer | Hold |
5
|
26.97€ | Buy/Sell | 45.15€ | 18.65% |
| ARGX Stock Forecast | argenx | Outperform |
4
|
349.90€ | Buy/Sell | 531.81€ | 25.18% |
| GMAB Stock Forecast | Genmab A/S | Outperform |
16
|
kr1.97k | Buy/Sell | kr2.71k | 30.07% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 500124 Stock Forecast | Dr. Reddy's Laboratories | Hold |
18
|
Rp5.95k | Buy/Sell | Rp5.67k | 1.66% |
| REC Stock Forecast | Recordati Industria Chimica e ... | Hold |
18
|
49.98€ | Buy/Sell | 48.61€ | 2.94% |
| HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£18.13 | Buy/Sell | £28.11 | 63.15% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ZEAL Stock Forecast | Zealand Pharma A/S | Outperform |
8
|
kr626.00 | Buy/Sell | kr357.00 | 30.19% |
| RICHTER Stock Forecast | Outperform |
18
|
Ft9.10k | Buy/Sell | Ft11.02k | 28.57% | |
| ORNBV Stock Forecast | Orion Oyj | Hold |
14
|
33.10€ | Buy/Sell | 42.52€ | 26.89% |
STADA Arzneimittel EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, STADA Arzneimittel's EBITDA has grown by 25.12%, rising from 677.58€M to 847.79€M. For the next year, 0 analysts project STADA Arzneimittel's EBITDA to drop by 12.07%, reaching 745.46€M. By 2030, professionals believe that STADA Arzneimittel's EBITDA will decrease by 11.33%, reaching 751.72€M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| KRKG Stock Forecast | Krka, d. d. | Buy |
18
|
124.50€ | Buy/Sell | 119.80€ | 14.46% |
| ALK B Stock Forecast | ALK-Abelló A/S | Outperform |
13
|
kr126.50 | Buy/Sell | kr109.25 | 5.14% |
| PBH Stock Forecast | Prestige Consumer Healthcare | Outperform |
16
|
$70.13 | Buy/Sell | $71.50 | 6.23% |
STADA Arzneimittel EBIT Forecast for 2023 - 2025 - 2030
In the last two years, STADA Arzneimittel's EBIT has grown, rising from 492.78€M to 631.91€M – a growth of 28.23%. According to 0 prominent analysts, STADA Arzneimittel's EBIT will fall by 13.88% in the next year, reaching 544.22€M. By 2030, professionals believe that STADA Arzneimittel's EBIT will decrease by 12.91%, reaching 550.34€M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MOR Stock Forecast | MorphoSys | Outperform |
6
|
67.70€ | Buy/Sell | 28.78€ | 0.44% |
| EVT Stock Forecast | Evotec | Outperform |
14
|
9.64€ | Buy/Sell | 37.33€ | 164.52% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£15.14 | Buy/Sell | £28.89 | 108.06% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALM Stock Forecast | Almirall | Outperform |
16
|
8.39€ | Buy/Sell | 11.39€ | 37.07% |
| COPN Stock Forecast | Cosmo Pharmaceuticals N.V. | Buy |
12
|
CHF75.30 | Buy/Sell | CHF76.55 | 24.93% |
| FAE Stock Forecast | Faes Farma | Hold |
18
|
3.28€ | Buy/Sell | 3.90€ | 11.28% |
.jpg)